United States of EuropeUnited States of Europe
analysisHealth

Fragmented health policies fail against mutating superbugs

Surging drug-resistant infections in European hospitals show why health security requires collective purchasing and shared surveillance.

By United States of Europe editorial team · How we write editorial

European health authorities have warned of increases exceeding 70% in drug-resistant infections such as Klebsiella pneumoniae and E. coli, according to a new European report. Strains of Klebsiella pneumoniae have now evolved to resist even the newest reserve antibiotics, threatening to push hospital wards back towards a pre-antibiotic era.

Health policy remains largely national, leaving individual member states to confront antimicrobial resistance in isolation. Spain highlights the problem: despite reducing overall antibiotic consumption, the country faces a deadly paradox as resistant infection rates continue to climb. Because pathogens cross borders effortlessly with patients and travel, separate national containment plans cannot stop the spread of mutating strains.

Health ministries understandably prefer to retain control over domestic hospital budgets and prescription guidelines to match local medical needs. Managing everyday healthcare delivered in local clinics belongs at the national or regional level.

Yet individual national markets lack the scale to incentivize pharmaceutical companies to develop fresh treatments. Pooled European purchasing power and joint research funding can create the market pull needed for new antibiotics, while shared surveillance networks can track resistant strains in real time across the continent.

Bacteria do not check passports at national frontiers. Europe can protect its health systems by treating antimicrobial resistance as a single, collective security challenge.

Drafted with AI, edited by the editor.

Sources

More from the editorial team